Ocular Therapeutix (OCUL) Announces Proposed Common Offering

Ocular Therapeutix™, Inc. (NASDAQ: OCUL) today announced that it has commenced an underwritten public offering of its common stock. In addition, the Company is expected to grant the underwriters of the offering a 30-day option to purchase up to an additional 15% of the shares to be sold in the public offering on the same terms and conditions. All of the shares in the offering are to be sold by the Company. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.

Jefferies LLC and Piper Sandler & Co. are acting as joint book-running managers for the offering.

The proposed offering is being made pursuant to a shelf registration statement on Form S-3 that was previously filed with and declared effective by the Securities and Exchange Commission (SEC). This offering will be made only by means of a prospectus supplement and the accompanying prospectus that form a part of the registration statement.

You May Also Be Interested In

• Singularity Future Technology closes $5M registered direct offering
• Jupiter Neurosciences prices $2M registered direct offering of shares
• Werewolf Therapeutics to merge with Ambros in $150M private placement